latest news on compounded tirzepatide FDA confirms shortage is still over, gives compounders a grace period How Much Weight Comes Back

Hepatic Safety: Hepatotoxicity And Liver Injury Liver injury is uncommon but documented

By week 12-16, most users on the pyridoxine compound have settled into a manageable routine

If you see particulates, cloudiness, or discoloration other than pink, do not use the vial

About 43% of large employer plans cover GLP-1 medications

A SURPASS-4 clinical trial involved patients with cardiovascular diseases such as peripheral arterial disease, coronary artery disease, stroke, and myocardial infarction

The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists